Emergent in $174m deal with AZ to expand manufacturing commitment
Emergent will produce commercial scale drug substance for AZ’s potential vaccine for COVID-19.
Archives for August 4, 2020
Lilly: Maximizing manufacturing capacity is key to COVID-19 antibody strategy
Eli Lilly cites need to maximize production capacity to explain decision to develop a single-antibody candidate against COVID-19.
Takeda sees ‘clear path’ to resolution of FDA warning letter
Takeda aims to have the plant that manufactures drugs including Entyvio and leuprorelin ready for re-inspection within 12 months.